Suicide Prevention Integration Into Task-shifted Mental Health Interventions
Launched by YALE UNIVERSITY · Jan 4, 2024
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to help prevent suicide among women in rural Pakistan by testing a special program called the Suicide Prevention Package (SuPP). The goal is to see how well this program can work within a current mental health treatment for depression. Researchers want to find out if it is easy to use and if people find it helpful. This study is important because it could lead to better mental health support for people living in areas with fewer resources, especially for those who need urgent help.
To be part of this trial, women must be fluent in Urdu, currently receiving care from a healthcare provider, and have access to a mobile phone. They also need to have a child who is three years old or younger or be pregnant. Participants will be followed for about six months, and the researchers hope to learn valuable information that can help improve mental health services for many people in similar situations. If you or someone you know fits these criteria and is interested in participating, it could be a chance to contribute to important changes in mental health care.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria for trial participants receiving the intervention:
- • Speak Urdu fluently
- • Be actively receiving care from a clinician
- • Have access to a mobile phone
- • Intending to reside in the study area for the entire duration of the follow up (approx. six months)
- • Has a child 3 years or under or is pregnant
- Exclusion Criteria for trial participants receiving the intervention:
- • Women requiring immediate inpatient care for any reason (medical or psychiatric)
- • Women who do not speak and/or comprehend Urdu language
- Inclusion Criteria for Peers and health system stakeholders:
- • Speak Urdu fluently
- • Be older than 18 at the time of recruitment
- • Have access to a mobile phone
- • Intending to reside in the study area for the entire duration of the follow up (approx. six months)
- Exclusion Criteria for Peers and health system stakeholders:
- • Women with untreated suicidality
- • Women who do not speak and/or comprehend Urdu language
About Yale University
Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Islamabad, Pakistan
Patients applied
Trial Officials
Ashley K Hagaman, PhD MPH
Principal Investigator
Yale School of Public Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported